Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma

Neehar D. Parikh, Amit G. Singal, David W. Hutton

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Fingerprint

Dive into the research topics of 'Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences